Doctors Note Logo

Published on: 8/18/2026

Why HPP Causes Tooth Loss and Bone Breaks: Critical Steps

Hypophosphatasia (HPP) stems from ALPL gene changes that lower alkaline phosphatase activity, allowing mineralization inhibitors to build up so bones stay soft and tooth-anchoring cementum fails, which explains early tooth loss with roots intact, plus stress fractures, pseudofractures, and slow-healing breaks. Critical steps include checking a low serum ALP level for your age and sex, genetic confirmation, avoiding bisphosphonates and high-dose vitamin D, protecting dental structure with specialist care, and discussing enzyme replacement therapy for qualifying cases. Severity ranges widely from infancy to adulthood, and low ALP can be mistaken for osteoporosis, so several important factors deserve attention before treatment decisions are made. See below to understand more, including the warning signs that call for urgent evaluation.

Because painless adult tooth loss, repeated fractures, and bone pain overlap with many other conditions, it helps to organize your symptoms before your next appointment, and a free, instant, online symptom check can flag likely explanations and point you toward the right specialist without a wait or a fee.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Why HPP Causes Tooth Loss and Bone Breaks: Critical Steps

Hypophosphatasia (HPP) is a rare inherited disorder that disrupts normal bone and tooth mineralization. By understanding the key biological steps behind HPP, you can see why affected individuals often experience premature tooth loss and fragile bones prone to fractures. Knowing the “hpp symptoms” to watch for, how the disease progresses, and when to seek professional help can guide you toward better outcomes.


1. Genetic Mutation and Enzyme Deficiency

  • HPP is caused by mutations in the ALPL gene, which provides instructions for making tissue-nonspecific alkaline phosphatase (TNSALP).
  • TNSALP is an enzyme found on the surface of bone-building cells (osteoblasts) and in developing tooth structures.
  • When TNSALP activity is low or absent, critical substrates build up and the mineralization process stalls.

Key hpp symptoms at this stage:

  • Bone pain, especially in the legs
  • Delayed walking or trouble with motor skills in infants
  • Early loss of baby teeth (before age 5)

2. Substrate Accumulation: PPi, PLP, PEA

Without sufficient alkaline phosphatase, several compounds that normally get broken down start to accumulate:

  • Inorganic pyrophosphate (PPi): A natural inhibitor of hydroxyapatite crystals, which are essential for hardening bone and tooth structures.
  • Pyridoxal-5′-phosphate (PLP): The active form of vitamin B₆, which can’t be used properly by nerves without TNSALP.
  • Phosphoethanolamine (PEA): Typically filtered out by healthy bones and kidneys.

High levels of PPi are especially harmful, because they block the very mineral that gives bones and teeth their strength.


3. Impaired Mineralization of Bone Matrix

Under normal conditions, osteoblasts lay down a collagen matrix that gets mineralized by depositing calcium and phosphate as hydroxyapatite crystals. In HPP:

  1. Elevated PPi surrounds the collagen matrix.
  2. PPi binds to early crystal nucleation sites.
  3. Crystal growth is halted.
  4. Result: Osteoid (unmineralized bone) accumulates, leading to soft, under-mineralized bone (osteomalacia or rickets).

Clinical consequences:

  • Bowed legs or knobby knees in children
  • Recurrent stress fractures in weight-bearing bones
  • Chronic bone pain and muscle weakness

4. Fragile Bones and Increased Fracture Risk

As bone mineral density falls, structural integrity weakens:

  • Bones bend under normal loads instead of holding firm.
  • Microcracks form and fail to heal properly.
  • Major fractures can occur with low-impact events—such as walking or minor falls.

Common fracture sites in HPP:

  • Wrists
  • Ankles
  • Ribs
  • Vertebrae

Managing fracture risk involves:

  • Low-impact exercises (swimming, cycling)
  • Fall prevention strategies
  • Orthopedic support (bracing, splints)

5. Dental Effects: Lack of Cementum and Tooth Loss

Teeth rely on a specialized mineralized layer called cementum to anchor roots into the jawbone. In HPP:

  • Insufficient alkaline phosphatase stalls cementum formation.
  • Roots remain poorly attached.
  • Baby teeth (primary teeth) tend to loosen early.
  • Permanent teeth may also be at risk.

Typical dental findings:

  • Shallow or absent tooth roots on X-ray
  • Gums that appear healthy but teeth that fall out
  • Increased risk of cavities and gum disease due to structural weakness

Dental management tips:

  • Gentle brushing with a soft brush
  • Regular check-ups with a dentist experienced in metabolic bone diseases
  • Early orthodontic evaluation to monitor erupting permanent teeth

6. Recognizing Other HPP Symptoms

Beyond bones and teeth, HPP can cause a spectrum of symptoms depending on age of onset and severity:

  • Infantile HPP: Severe bone deformities, failure to thrive, respiratory complications.
  • Childhood HPP: Growth delay, waddling gait, delayed walking, muscle weakness.
  • Adult HPP: Stress fractures, joint pain, fatigue, chondrocalcinosis (calcium pyrophosphate crystal deposition in joints).
  • Odontohypophosphatasia: Dental issues with minimal or no bone involvement.

Always keep track of any new or worsening signs. If you notice multiple hpp symptoms—especially pain, fractures, or unexpected tooth loss—consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.


7. Diagnosis and Laboratory Clues

Confirming HPP involves:

  • Measuring serum alkaline phosphatase (ALP): typically low in HPP.
  • Checking levels of PPi, PLP, and PEA: often elevated.
  • Genetic testing for ALPL mutations.
  • Imaging studies (X-rays, DXA scans) to assess bone density and structure.

Because low ALP can occur in other conditions, a full clinical evaluation is essential.


8. Treatment Options

While there’s no cure that corrects the underlying genetic defect, treatments focus on reducing symptoms and improving quality of life:

  • Enzyme Replacement Therapy (asfotase alfa): Replaces deficient TNSALP, improves bone mineralization, reduces fracture risk.
  • Pain Management: Analgesics, physical therapy, low-impact activities.
  • Orthopedic Interventions: Surgical correction of severe deformities, support devices.
  • Dental Care: Early and frequent dental visits, protective sealants, possible implants or dentures for missing teeth.

Each treatment plan should be tailored to the individual’s age, severity, and overall health.


9. Living with HPP: Practical Tips

  • Maintain a balanced diet rich in calcium and vitamin D (unless otherwise directed by your doctor).
  • Avoid high-impact sports if you have fragile bones.
  • Use mobility aids (canes, walkers) as needed to prevent falls.
  • Keep a dental hygiene routine even if teeth are loose—prevention of infections is crucial.
  • Join support groups or patient communities to connect with others facing HPP.

10. When to Speak to a Doctor

HPP can range from mild to life-threatening. Always reach out to a healthcare professional if you experience:

  • Severe bone pain or unexpected fractures
  • Early loss of baby or permanent teeth
  • Difficulty breathing or chest deformities (in infants)
  • Signs of infection around loose teeth or surgical sites

A prompt evaluation can prevent complications and improve long-term outcomes.


Remember: You don’t have to face hpp symptoms alone. For a quick, confidential review of your concerns, try a free, online symptom check, using the doctor approved Ubie Symptom Checker. And if anything feels serious or life-threatening, be sure to speak to a doctor right away.

(References)

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. 2000. PMID: 25905277.

  • * Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Marini JC, Dang Do AN. Osteogenesis Imperfecta. 2000. PMID: 25905334.

  • * Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. PMID: 26893260.

  • * Linglart A, Biosse-Duplan M. Hypophosphatasia. Curr Osteoporos Rep. 2016 Jun;14(3):95-105. doi: 10.1007/s11914-016-0309-0. PMID: 27084188.

  • * Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25. PMID: 28888853.

  • * Fenn JS, Lorde N, Ward JM, Borovickova I. Hypophosphatasia. J Clin Pathol. 2021 Oct;74(10):635-640. doi: 10.1136/jclinpath-2021-207426. Epub 2021 Apr 30. PMID: 33931563.

  • * Tournis S, Yavropoulou MP, Polyzos SA, Doulgeraki A. Hypophosphatasia. J Clin Med. 2021 Dec 1;10(23). doi: 10.3390/jcm10235676. Epub 2021 Dec 1. PMID: 34884378; PMCID: PMC8658462.

  • * Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.

  • * Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031. PMID: 36510335; PMCID: PMC10166271.

  • * Reis FS, Lazaretti-Castro M. Hypophosphatasia: from birth to adulthood. Arch Endocrinol Metab. 2023 May 25;67(5):e000626. doi: 10.20945/2359-3997000000626. PMID: 37249457; PMCID: PMC10665056.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.